Keynote 224 Results Calendar. Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: A phase ii study of pembrolizumab (pembro) in patients with advanced.


Keynote 224 Results Calendar

In the keynote study, a conventional dose of pembrolizumab, 200 mg iv every 3 weeks, was used in a cohort of patients who had failed or progressed on. Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (hcc):

Keynote 224 Results Calendar Images References :